Denali TherapeuticsDNLI

Denali reported its first full quarter of sales for Avlayah, a treatment for a rare genetic disorder called Hunter syndrome. The drug brought in $3.6 million in its first few months on the market. While this is a small number today, it is a major milestone because it proves the company can successfully turn its lab research into a commercial product.

The company also strengthened its finances by selling a Priority Review Voucher for $195 million. These vouchers are special credits the government gives to companies that develop drugs for rare diseases, which can be sold to other firms to speed up their own drug approvals. This sale helped boost Denali's cash to over $1.1 billion, giving it a long runway to fund its other expensive trials for Alzheimer's and Parkinson's diseases.

Source: GlobeNewsWire

Key highlights

• Avlayah commercial launch: Denali started selling Avlayah for Hunter syndrome in April after receiving FDA accelerated approval on March 25, 2026. This is the first medicine ever approved to use a specialized transport technology to cross the blood-brain barrier, confirming the company can successfully turn its science into a sellable product.
• Strong cash position: The company ended the quarter with $1.05 billion in cash and investments, which was boosted by a $200 million payment from a royalty deal with Royalty Pharma. This deep reserve is critical because it gives the company several years of funding to develop its clinical pipeline without needing to immediately issue more stock.
• Development costs falling: Research and development spending fell by $12.4 million to $103.8 million compared to the same time last year. The drop happened because the company finished making the initial commercial supply of its new drug and spent less on older programs, showing that costs are stabilizing even as more drugs move toward final testing.
• Full rights regained: Denali took back full control of its frontotemporal dementia drug, DNL593, after Takeda ended their partnership for strategic reasons. This means Denali will no longer share future profits on this drug, which has finished enrolling all 40 patients in its current study and expects to report data by the end of 2026.
• Road ahead for data: Management expects several major updates through 2027, including results from a mid-stage Parkinson's disease study in mid-2026 and a regulatory filing for a Sanfilippo syndrome treatment in 2027. These milestones are the primary drivers for the stock because they will determine if Denali's success with Hunter syndrome can be repeated in much larger markets like Parkinson's.

Our take: This was a landmark quarter for Denali, marked by the transition from a research firm to a commercial company with its first approved drug. The billion dollar cash pile and successful launch of Avlayah prove the technology works and the business is well funded, which strengthens the long term case for its neurodegenerative disease pipeline.